NKTR-214

DRUG8 trials

Conditions

Advanced CancerEpendymomaEwing SarcomaHead and Neck CancerHigh-grade GliomaLeukemia and LymphomaLymphoma, Non-HodgkinMedulloblastoma

Phase 1

A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors

CompletedNCT02869295

Nektar TherapeuticsUnspecified Adult Solid Tumor, Protocol Specific

Start: 2015-12-31End: 2018-10-31Updated: 2021-07-29

Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors

TerminatedNCT03138889

Nektar TherapeuticsNon-Small Cell Lung Cancer

Start: 2017-06-09End: 2022-08-24Updated: 2023-03-10

An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors

CompletedNCT03745807

Bristol-Myers SquibbAdvanced Cancer

Start: 2019-04-09End: 2019-12-18Updated: 2021-10-04

A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)

WithdrawnNCT03772288

Calithera Biosciences, IncLymphoma, Non-Hodgkin

Start: 2019-04-03End: 2021-11-17Updated: 2023-02-08

A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

TerminatedNCT04730349

Bristol-Myers SquibbEpendymoma, Ewing Sarcoma, High-grade Glioma +7

Start: 2021-06-03End: 2022-06-22Updated: 2023-03-24

Phase 2

A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Active, not recruitingNCT03282344

Memorial Sloan Kettering Cancer CenterSARCOMA

Start: 2017-09-12End: 2027-09-01Updated: 2026-07-22

Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma

TerminatedNCT04936841

University of Wisconsin, MadisonHead and Neck Cancer

Start: 2021-08-05End: 2022-10-04Updated: 2024-04-04

Phase 3

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

CompletedNCT03635983

Bristol-Myers SquibbMelanoma

Start: 2018-09-21End: 2024-03-19Updated: 2025-04-01

npj Precision Oncology2024-07-184 citations

Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results

Journal of Clinical Oncology2023-08-3155 citations

Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer

Future Oncology2023-05-185 citations

1473 Mechanism of action of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in patients with unresectable or metastatic melanoma from the phase 3 randomized open-label PIVOT IO-001 clinical trial

2022-11-012 citations

Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma.

2022-06-1643 citations

Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8<sup>+</sup> T cell cytotoxicity over BEMPEG+RT

Journal for ImmunoTherapy of Cancer2022-04-0129 citations

420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study

Regular and Young Investigator Award Abstracts2020-11-017 citations

Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design

Future Oncology2020-07-2928 citations

Pilot study of NKTR214 and nivolumab in patients with sarcomas.

Journal of Clinical Oncology2019-05-209 citations

CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL).

Journal of Clinical Oncology2019-05-204 citations

PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2018-05-203 citations

TAK-659 in combination with NKTR-214 and anti-PD-1 therapy leads to complete and sustained tumor regression and immune memory in pre-clinical syngeneic models.

Journal of Clinical Oncology2018-05-20

Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy.

Journal of Clinical Oncology2017-05-2022 citations

NKTR-214

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Related Papers